DUBLIN–(BUSINESS WIRE)–The “U.S. Continuous Renal Replacement Therapy Market 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.

The U.S. continuous renal replacement therapy market size is expected to reach USD 957.2 million by 2028. It is expected to expand at a CAGR of 6.1% from 2021 to 2028.

The U.S. market is expected to grow owing to the growing number of ICU patients with Acute Kidney Injury (AKI), along with the increasing incidence of sepsis.

Moreover, COVID-19 has positively impacted the market growth. In addition, the presence of well-established key players in the country focusing on developing and commercializing technologically advanced devices and initiatives undertaken by the government to increase the awareness about continuous renal replacement therapy (CRRT) is expected to boost the market growth during the forecast period.

The increasing prevalence of fluid overload, which frequently occurs in AKI patients in critical care units, is a key factor boosting the demand for CRRT devices. Moreover, the FDA has implemented precise laws on manufacturers to endorse the availability of high-quality CRRT devices in ICUs. This is expected to help create lucrative growth opportunities in the U.S. market in the near future.

Leading players such as Baxter International, Inc.; Fresenius Kabi; and Medtronic are investing extensively in R&D to develop technologically advanced CRRT devices. Baxter, for example, has developed a PRISMAFLEX critical care system. It is a versatile platform that provides personalized therapy based on a patient’s comfort and suitability.

Furthermore, B. Braun’s Diapact CRRT system is equipped with modern technology that enables the effective treatment of AKI and kidney disorders. The critical blood filtering process is carried out accurately and without obstructing patients’ recovery.

Such advancements in CRRT systems, combined with innovation, are expected to result in the increased adoption of CRRT systems, which is anticipated to boost the U.S. CRRT market growth in the near future.

U.S. Continuous Renal Replacement Therapy Market Report Highlights

  • In terms of product, the liquids segment dominated the market in terms of revenue in 2020. The growing number of manufacturers supplying dialysate and replacement fluids for RRT is contributing to the segment growth
  • The disposables product segment is projected to expand significantly during the forecast period owing to the increasing use of hemofilter, fluids, charcoal filters, and other consumables in CRRT treatments
  • By modality, in 2020, the Continuous Venovenous Hemodialysis (CVVHD) segment dominated the market in terms of a number of procedures/treatments. The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to expand at the highest volume-based CAGR during the forecast period

Market Dynamics

Market Driver Analysis

  • Increasing Prevalence of Acute Kidney Injury (Aki) and Associated Chronic Kidney Disease
  • Rising Geriatric Population
  • Technological Advancements in CRRT Machines
  • Presence of a Large Number of Hospitals & Dialysis Clinics and Increasing Healthcare Expenditure

Market Restraint Analysis

  • Complications Associated with Usage of CRRT in Critically Ill Neonates

Market Opportunity Analysis

  • Advancements in CRRT Data Management

Market Challenge Analysis

  • Availability of Alternative Therapies

Continuous Renal Replacement Therapy Market Analysis Tools

  • SWOT Analysis, by Pest
  • Porter’s Five Forces Analysis


Major Deals & Strategic Alliances Analysis

  • Geographical Expansion
  • Product Launches


COVID-19 Market Impact

  • Supply Chain
  • Changing Market Trends

Companies Mentioned

  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen Ag
  • Baxter
  • Fresenius Medical Care Ag
  • Medtronic
  • Nipro Corporation

For more information about this report visit https://www.researchandmarkets.com/r/v227hz



Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900